GlassScriptPhysician profile
Raleigh Cutrer
NPI 1700240843
$6,171.19
in general payments reported to CMS, 2019-2025
58 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $276 · 2021: $929 · 2022: $581 · 2023: $697 · 2024: $1,882 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $155.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $603.66 | 2021-2025 | |
| Seagen INC. | $330.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.96 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Genentech USA, INC. | $297.55 | 2019-2025 | Polivy, Venclexta, Columvi |
| Amgen INC. | $295.88 | 2019-2023 | Blincyto, Nplate, Vectibix |
| Novartis Pharmaceuticals Corporation | $267.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $265.32 | 2020-2025 | Opdivo |
| Glaxosmithkline, LLC. | $250.44 | 2022-2025 | Ojjaara, Blenrep |
| Pfizer INC. | $240.03 | 2019-2025 | |
| Lilly USA, LLC | $230.11 | 2020-2025 | Verzenio, Retevmo, Jaypirca |
| Celgene Corporation | $207.77 | 2021-2025 | Reblozyl, Breyanzi, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $206.40 | 2021-2025 | Ninlaro, Alunbrig |
| Janssen Biotech, INC. | $205.43 | 2024-2025 | Tecvayli, Rybrevant, Talvey |
| Astellas Pharma US INC | $201.66 | 2021-2025 | Cresemba, Padcev, Vyloy |
| Daiichi Sankyo INC. | $197.26 | 2023-2025 | Vanflyta, Enhertu, Injectafer |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $195.89 | 2023-2024 | Venclexta |
| Incyte Corporation | $174.96 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Beigene USA, INC. | $164.94 | 2021-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $123.19 | 2023-2025 | Keytruda |
| Alexion Pharmaceuticals, INC. | $119.57 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $106.90 | 2022-2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $79.47 | 2021-2025 | Gavreto, Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $69.87 | 2022-2024 | Ayvakit |
| Beone Medicines USA, INC. | $65.48 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $62.84 | 2023-2025 | Libtayo |
| Kyowa Kirin, INC. | $58.59 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $54.92 | 2021-2024 | Onivyde |
| Sobi, INC | $52.97 | 2025 | |
| Tempus Ai, INC | $49.24 | 2024-2025 | Xt Cdx |
| Kite Pharma, INC. | $46.83 | 2024-2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $41.02 | 2024 | |
| Immunocore Limited | $40.82 | 2023-2024 | Kimmtrak |
| Eisai INC. | $40.82 | 2023-2024 | |
| Emd Serono, INC. | $36.08 | 2023-2025 | Bavencio |
| Syndax Pharmaceuticals, INC. | $35.08 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.86 | 2023 | Zepzelca |
| Springworks Therapeutics, INC. | $31.70 | 2025 | Ogsiveo |
| Tesaro, INC. | $28.60 | 2019 | |
| Puma Biotechnology, INC. | $25.70 | 2021-2022 | |
| Acceleron Pharma, INC. | $24.61 | 2021 | |
| Genmab U.S., INC. | $24.01 | 2024 | Epkinly |
| Geron Corporation | $21.31 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $20.29 | 2020 | |
| Sun Pharmaceutical Industries INC. | $20.18 | 2023 | Yonsa, Odomzo |
| Taiho Oncology, INC. | $19.83 | 2025 | |
| Boston Scientific Corporation | $19.74 | 2024 | Spaceoar Vue System - 10ml |
| Pharmaessentia USA Corporation | $18.01 | 2025 | Besremi |
| Myriad Genetic Laboratories, INC. | $16.81 | 2024 | Myrisk |
| Acrotech Biopharma INC. | $16.80 | 2024 | Beleodaq |
| Alnylam Pharmaceuticals INC. | $16.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.37 | 2020 | |
| Caris Mpi, INC. | $16.19 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $15.24 | 2023 | Monoferric |
| Foundation Medicine, INC. | $13.29 | 2021 | |
| Secura Bio, INC. | $12.25 | 2022 | |
| Morphosys, US INC. | $11.39 | 2021 | |
| Servier Pharmaceuticals LLC | $10.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raleigh Cutrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.